Stempoint Capital’s Biohaven BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.8M Sell
1,064,200
-530,291
-33% -$5.71M 2.73% 9
2026
Q1
$13.5M Buy
+1,594,491
New +$17.4M 2.58% 11
2025
Q4
Sell
-1,017,311
Closed -$15.3M 88
2025
Q3
$15.3M Buy
1,017,311
+842,557
+482% +$12.3M 3.06% 9
2025
Q2
$2.47M Sell
174,754
-75,810
-30% -$1.35M 0.79% 35
2025
Q1
$6.02M Buy
250,564
+64,151
+34% +$2.26M 1.92% 22
2024
Q4
$6.96M Sell
186,413
-30,027
-14% -$1.4M 1.74% 24
2024
Q3
$10.8M Sell
216,440
-16,815
-7% -$654K 3.24% 10
2024
Q2
$8.1M Buy
233,255
+149,794
+179% +$5.92M 2.38% 16
2024
Q1
$4.56M Sell
83,461
-27,893
-25% -$1.38M 1.21% 25
2023
Q4
$4.77M Buy
+111,354
New +$3.46M 1.27% 27

Other funds holding BHVN

Stempoint Capital's BHVN Position: Q2 2026 in Review

Stempoint Capital reduced its Biohaven (BHVN) stake by 33% in Q2 2026, selling an estimated $5.71M and leaving 1,064,200 shares worth $15.8M. The position accounts for 2.73% of the portfolio, ranked #9.

Stempoint Capital first reported a position in BHVN in Q4 2023 and has held it in 10 quarters since. 295 funds tracked by Wall St. Rank hold BHVN as of Q2 2026.

  • Stempoint Capital held 1,064,200 shares of Biohaven worth $15.8M as of Q2 2026.
  • Stempoint Capital sold 530,291 Biohaven shares in Q2 2026, an estimated $5.71M.
  • Biohaven made up 2.73% of Stempoint Capital's portfolio in Q2 2026, its #9 holding.
  • Stempoint Capital first reported a position in Biohaven in Q4 2023 and has held it in 10 quarters since.
  • 295 funds tracked by Wall St. Rank held Biohaven as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.